A Fc-VEGF chimeric fusion enhances PD-L1 immunotherapy via inducing immune reprogramming and infiltration in the immunosuppressive tumor microenvironment.
Cheng-Liang KuoHan-Yu ChouHui-Wen LienChia-An YehJing-Rong WangChung-Hsing ChenChi-Chen FanChih-Ping HsuTing-Yu KaoTai-Ming KoAlan Yueh-Luen LeePublished in: Cancer immunology, immunotherapy : CII (2022)
In short, Fc-VFD fusion normalizes intratumor vasculature to reprogram the immunosuppressive TME and enhance cancer immunotherapy.